Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.39 |
| ▸ | BCL2 | P10415 | 5/20 | 0.33 |
| ▸ | BECN1 | Q14457 | 4/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14980625 | 0.87 | BACE1 (0.39) | BACE1 | |
| SCHEMBL2376786 | 0.84 | BACE1 (0.42) | BACE1BCL2BECN1AKR1B1 | |
| SCHEMBL12246351 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL12244966 | 0.73 | BACE1 (0.46) | BACE1AKR1B1 | |
| SCHEMBL7958777 | 0.69 | BACE1 (0.45) | BACE1BCL2BECN1AKR1B1 | |
| SCHEMBL12245450 | 0.66 | BACE1 (0.51) | BACE1 | |
| SCHEMBL12245408 | 0.66 | BACE1 (0.53) | BACE1 | |
| SCHEMBL12245407 | 0.66 | BACE1 (0.53) | BACE1 | |
| SCHEMBL1822883 | 0.66 | BACE1 (0.41) | BACE1BCL2BECN1AKR1B1 | |
| SCHEMBL7934145 | 0.66 | BACE1 (0.38) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | BACE1 1/4885BCL2 1248/4885BECN1 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.